

11
Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 57656

Manuscript Type: ORIGINAL ARTICLE

Comparison of Gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Hyung-Il Seo

Match Overview

1	Internet 82 words crawled on 08-Jun-2020 www.wjgnet.com	2%
2	Internet 21 words crawled on 02-Aug-2020 www.nature.com	1%
3	Internet 21 words crawled on 27-May-2020 es.scribd.com	1%
4	Internet 16 words crawled on 30-Jul-2020 www.oncotarget.com	<1%
5	Crossref 14 words "posters", <i>Annals of Oncology</i> , 06/01/2006	<1%
6	Crossref 14 words Inhwan Hwang, Jihoon Kang, Hei Nga Natalie Ip, Jae Ho J eong, Kyu-pyo Kim, Heung-Moon Chang, Changhoon Yoo,	<1%
7	Internet 14 words ir.ymlib.yonsei.ac.kr	<1%
8	Crossref 14 words B. Anton, F. Lonao Muñoz, D. Gutierrez Abad, M. De Torres	<1%



ALL

IMAGES

VIDEOS

29,900 Results

Any time ▾

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the ...

<https://www.ncbi.nlm.nih.gov/pubmed/29616439>

1. Invest New Drugs. 2018 Aug;36(4):732-741. doi: 10.1007/s10637-018-0598-5. Epub 2018 Apr 3. **Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.**

Cited by: 27

Author: Jihoon Kang, Jihoon Kang, Inhwan Hwang...

Publish Year: 2018

Efficacy and safety of second-line nab-paclitaxel plus ...

<https://journals.sagepub.com/doi/full/10.1177/1758835920923424>

Kang, J, Hwang, I, Yoo, C, et al **Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.** Invest New Drugs 2018 ; 36: 732 – 741 .

Author: Heejung Chae, Hye Hyun Jeong, Jaeky... Publish Year: 2020

Comparative Effectiveness of Gemcitabine plus Nab ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520876>

Apr 05, 2019 · Gemcitabine and nab-paclitaxel (GEM-NAB) and the combination of 5-fluorouracil, oxaliplatin, and irinotecan (FOLFIRINOX) are valid **first-line** options for advanced or **metastatic pancreatic cancer** (mPC). However, no randomized trials comparing the two schemes ...

Cited by: 8

Author: Sara Pusceddu, Michele Ghidini, Martina ...

Publish Year: 2019

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616879>

May 29, 2019 · 1. Introduction. **Pancreatic cancer** is the seventh leading cause of cancer-related death, with more than 330,000 deaths worldwide annually []. Patients with **pancreatic cancer** have a poor prognosis, and the overall five-year survival rate is only 8%, since **pancreatic cancer** is often diagnosed in an advanced stage with locally-advanced and/or **metastatic** lesions [].

Cited by: 2

Author: Naoki Mita, Takuji Iwashita, Shinya Uemu...

Publish Year: 2019

Nab-paclitaxel plus gemcitabine for metastatic pancreatic ...



ALL

IMAGES

VIDEOS

67,100 Results

Any time ▾

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for ...

<https://www.ncbi.nlm.nih.gov/pubmed/29846765>

Since **pancreatic cancer** is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. **METHODS:** Between March 2014 and April 2017, **FOLFIRINOX (FFX)** or **gemcitabine plus nab-paclitaxel (G-nab)** was used as first-line therapy to treat 27 patients with locally advanced and **metastatic pancreatic cancer** ...

Cited by: 10

Author: Junko Tahara, Kyoko Shimizu, Nao Otsuka, ...

Publish Year: 2018

Comparison of FOLFIRINOX and Gemcitabine Plus Nab ...

<https://pubmed.ncbi.nlm.nih.gov/32604162>

Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry FFX and GNP showed similar efficacy and comparable toxicity in MPC patients.

Author: Jong-Chan Lee, Sang Myung Woo, Don...

Publish Year: 2020

Comparative Effectiveness of nab-Paclitaxel Plus ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182639>

Sep 12, 2018 · **Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States** Sunnie Kim , 1 James E. Signorovitch , 2 Hongbo Yang , 2 Oscar Patterson-Lomba , 2 Cheryl Q. Xiang , 2 Brian Ung , 3 Monika Parisi , 3 and John L. Marshall 4

Cited by: 12

Author: Sunnie Kim, James E. Signorovitch, Hongb...

Publish Year: 2018

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the ...

<https://pubmed.ncbi.nlm.nih.gov/29616439>

Purpose **nab-paclitaxel plus gemcitabine (AG)** and **FOLFIRINOX** have been established as standard first-line treatment in **metastatic pancreatic cancer (mPC)**. We performed retrospective analysis comparing the efficacies of **AG and FOLFIRINOX** in daily practice setting. **Materials and Methods** We analyzed 308 ...



76,300 Results Any time ▾

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for ...

<https://www.ncbi.nlm.nih.gov/pubmed/29846765>

Since **pancreatic cancer** is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. **METHODS:** Between March 2014 and April 2017, **FOLFIRINOX (FFX)** or **gemcitabine plus nab-paclitaxel (G-nab)** was used as first-line therapy to treat 27 patients with locally advanced and **metastatic pancreatic cancer** ...

Cited by: 11 **Author:** Junko Tahara, Kyoko Shimizu, Nao Otsuk...
Publish Year: 2018

Comparative Effectiveness of nab-Paclitaxel Plus ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182639>

Sep 12, 2018 - Comparative Effectiveness of **nab-Paclitaxel Plus Gemcitabine** vs **FOLFIRINOX** in **Metastatic Pancreatic Cancer**: A Retrospective Nationwide Chart Review in the United States Sunnie Kim , 1 James E. Signorovitch , 2 Hongbo Yang , 2 Oscar Patterson-Lomba , 2 Cheryl Q. Xiang , 2 Brian Ung , 3 Monika Parisi , 3 and John L. Marshall 4

Cited by: 13 **Author:** Sunnie Kim, James E. Signorovitch, Hon...
Publish Year: 2018

Comparison of FOLFIRINOX and Gemcitabine Plus Nab ...

<https://pubmed.ncbi.nlm.nih.gov/32604162>

Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. Using **Korean Pancreatic Cancer (K-PaC) Registry FFX** and **GNP** showed similar efficacy and comparable toxicity in MPC patients.

Author: Jong-Chan Lee, Sang Myung Woo, D... **Publish Year:** 2020

Comparative Effectiveness of Gemcitabine plus Nab ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520876>

Apr 05, 2019 - **Gemcitabine and nab-paclitaxel (GEM-NAB)** and the combination of **5-fluorouracil**, oxaliplatin, and irinotecan (**FOLFIRINOX**) are valid **first-line options** for advanced or **metastatic pancreatic cancer** (mPC). However, no randomized trials **comparing** ...

Cited by: 13 **Author:** Sara Pusceddu, Michele Ghidini, Martina ...
Publish Year: 2019